

13<sup>th</sup> November, 2024

To

BSE Limited  
Corporate Relationship Department  
P J Towers  
Dalal Street, Fort  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 13<sup>th</sup> November, 2024

**Ref:** Security Code: 524520; Security ID: KMCSHIL

In terms of provisions of Regulation 30 (read with Part A of Schedule III) and Regulations 33 and 52 of SEBI (LODR) Regulations 2015, the Board of Directors at its meeting held today, 13<sup>th</sup> November 2024, have inter-alia, approved the Standalone Unaudited Financial results for the Quarter and half year ended 30<sup>th</sup> September, 2024 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 10:31 am and concluded at 11:15 am

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**


**Dr S Manivannan**  
**Managing Director**  
**DIN: 00910804**



**Regd. Office :**

**KMC Speciality Hospitals (India) Ltd**

CIN - L85110TN1982PLC009781

No. 6, Royal Road, Cantonment, Trichy - 620 001.

**T** 0431 - 4077777 **F** 0431 - 2415402

**E** info@kauveryhospital.com **W** www.kauveryhospital.com

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF KMC SPECIALITY HOSPITALS (INDIA) LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC Speciality Hospitals (India) Limited** (the "Company"), for the quarter and six months ended September 30, 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells**  
Chartered Accountants  
(Firm's Registration No. 008072S)



*Rekha Bai*

**Rekha Bai**  
(Partner)  
(Membership No. 214161)  
UDIN: 24214161BKEXFN6392

Place: Chennai  
Date: November 13, 2024  
KMC/RB/PB/Q2 2024-25

Statement of unaudited financial results for the quarter and six months ended September 30, 2024


(Rs. In Lakhs except EPS)

Particulars	Quarter ended			Six months ended		Year ended
	September 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)	March 31, 2024 (Audited)
<b>1 Income</b>						
a) Revenue from operations	5,623.07	5,306.80	4,231.98	10,929.87	8,316.30	17,717.53
b) Other income	45.91	62.09	57.22	108.00	221.23	355.99
<b>Total income</b>	<b>5,668.98</b>	<b>5,368.89</b>	<b>4,289.20</b>	<b>11,037.87</b>	<b>8,537.53</b>	<b>18,073.52</b>
<b>2 Expenses</b>						
a) Cost of materials consumed	247.62	184.10	79.87	431.72	166.45	358.66
b) Purchase of stock-in-trade	568.65	587.27	519.52	1,155.92	1,004.43	2,066.97
c) Changes in inventories of stock-in-trade	(4.27)	(44.46)	0.72	(48.73)	20.85	16.80
d) Employee benefits expense	1,299.07	1,256.45	879.62	2,555.52	1,812.58	3,826.71
e) Finance costs	269.33	208.03	21.45	477.36	42.29	116.39
f) Depreciation and amortisation expense	495.24	408.00	218.91	903.24	433.44	922.36
g) Other expenses	2,259.83	2,029.83	1,640.94	4,289.66	3,192.91	6,709.81
<b>Total expenses</b>	<b>5,135.47</b>	<b>4,629.22</b>	<b>3,361.03</b>	<b>9,764.69</b>	<b>6,672.95</b>	<b>14,017.70</b>
<b>3 Profit before tax (1-2)</b>	<b>533.51</b>	<b>739.67</b>	<b>928.17</b>	<b>1,273.18</b>	<b>1,864.58</b>	<b>4,055.82</b>
<b>4 Income tax expense</b>						
a) Current tax	163.41	130.67	248.22	294.08	506.43	877.33
b) Deferred tax	(18.31)	58.28	(7.00)	39.97	(22.44)	140.56
<b>Total income tax expense</b>	<b>145.10</b>	<b>188.95</b>	<b>241.22</b>	<b>334.05</b>	<b>483.99</b>	<b>1,017.89</b>
<b>5 Profit for the period (3-4)</b>	<b>388.41</b>	<b>550.72</b>	<b>686.95</b>	<b>939.13</b>	<b>1,380.59</b>	<b>3,037.93</b>
<b>6 Other comprehensive loss</b>						
Items that will not be reclassified subsequently to profit or loss						
(a) Re-measurement of defined benefit plans (net)	(1.85)	(10.08)	(19.01)	(11.93)	(19.37)	(40.32)
(b) Income tax relating to items that will not be reclassified to profit or loss	0.46	2.54	4.79	3.00	4.88	10.15
<b>Total other comprehensive loss, net of tax</b>	<b>(1.39)</b>	<b>(7.54)</b>	<b>(14.22)</b>	<b>(8.93)</b>	<b>(14.49)</b>	<b>(30.17)</b>
<b>7 Total comprehensive income (5+6)</b>	<b>387.02</b>	<b>543.18</b>	<b>672.73</b>	<b>930.20</b>	<b>1,366.10</b>	<b>3,007.76</b>
<b>8 Paid-up equity share capital (Face value of Re.1/- each)</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>
<b>9 Reserves i.e. Other equity</b>						<b>12,727.12</b>
<b>10 Earnings per share (EPS) of Re. 1/- each :</b>						
Basic	0.24	0.34	0.42	0.58	0.85	1.86
Diluted	0.24	0.34	0.42	0.58	0.85	1.86
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)




Statement of assets and liabilities

Particulars		(Rs. in Lakhs)	
		As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
<b>A Assets</b>			
<b>1 Non-current assets</b>			
(a)	Property, plant and equipment	22,882.63	19,555.14
(b)	Right-of-use assets	859.76	964.94
(c)	Capital work-in-progress	644.74	64.45
(d)	Investment property	40.43	40.43
(e)	Other intangible assets	5.14	6.48
(f)	Financial assets		
	(i) Investments	0.38	0.38
	(ii) Other financial assets	599.54	425.69
(g)	Income tax assets (net)	417.69	288.70
(h)	Other non-current assets	650.61	1,673.45
	<b>Sub-total - Non-current assets</b>	<b>28,100.92</b>	<b>23,019.66</b>
<b>2 Current assets</b>			
(a)	Inventories	324.14	204.85
(b)	Financial assets		
	(i) Trade receivables	654.14	438.18
	(ii) Cash and cash equivalents	256.56	484.57
	(iii) Bank balances other than (ii) above	409.90	1,783.19
	(iv) Loans	25.03	16.45
	(v) Other financial assets	421.30	300.10
(c)	Other current assets	199.77	124.55
	<b>Sub-total - Current assets</b>	<b>2,290.84</b>	<b>3,351.89</b>
	<b>Total - Assets</b>	<b>28,391.76</b>	<b>26,371.55</b>
<b>Equity and liabilities</b>			
<b>1 Equity</b>			
(a)	Equity share capital	1,630.85	1,630.85
(b)	Other equity	13,657.34	12,727.12
	<b>Sub-total - Equity</b>	<b>15,288.19</b>	<b>14,357.97</b>
<b>2 Non-current liabilities</b>			
(a)	Financial Liabilities		
	(i) Borrowings	7,524.04	6,385.20
	(ii) Lease Liabilities	622.07	762.61
(b)	Provisions	177.90	148.73
(c)	Deferred tax liabilities (net)	100.76	63.79
(d)	Other non-current liabilities	9.60	8.11
	<b>Sub-total - Non-current liabilities</b>	<b>8,434.37</b>	<b>7,368.44</b>
<b>3 Current liabilities</b>			
(a)	Financial liabilities		
	(i) Borrowings	808.31	854.84
	(ii) Lease liabilities	232.29	179.00
	(iii) Trade payables		
	(A) Total outstanding dues of micro enterprises and small enterprises	200.57	28.59
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,166.57	727.39
	(iv) Other financial liabilities	1,645.75	2,379.96
(b)	Other current liabilities	350.53	292.99
(c)	Provisions	265.18	182.37
	<b>Sub-total - Current liabilities</b>	<b>4,669.20</b>	<b>4,645.14</b>
	<b>Sub-total - Liabilities</b>	<b>13,103.57</b>	<b>12,013.58</b>
	<b>Total - Equity and liabilities</b>	<b>28,391.76</b>	<b>26,371.55</b>



Statement of unaudited cashflow statement


		(Rs. In Lakhs)	
Particulars	For the six months ended September 30, 2024 (Unaudited)	For the six months ended September 30, 2023 (Unaudited)	
<b>A</b>	<b>Cash flows from operating activities</b>		
	Profit before tax	1,273.18	1,864.58
	Adjustments:		
	Depreciation and amortisation expense	903.24	433.44
	Provision for loss allowance	19.99	(6.66)
	Bad debts written off	11.29	31.13
	Provision utilised for write off	(11.29)	-
	Rental Income	(10.81)	(7.51)
	Finance costs	477.36	42.29
	Interest income from banks	(41.01)	(113.34)
	Interest income from others	(3.23)	(30.52)
	<b>Operating profit before working capital / other changes</b>	<b>2,618.72</b>	<b>2,213.41</b>
	<u>Adjustment for (increase)/decrease in operating assets</u>		
	Inventories	(119.29)	10.21
	Trade receivables	(235.94)	(119.73)
	Other financial assets and other assets - Non-current	(37.75)	(47.66)
	Other financial assets and other assets - Current	(213.29)	(25.55)
	<u>Adjustment for increase/(decrease) in operating liabilities</u>		
	Trade payables	599.23	47.74
	Liabilities and provisions	178.61	(66.29)
	<b>Cash generated from operations</b>	<b>2,790.29</b>	<b>2,012.13</b>
	Direct taxes paid (net)	(423.06)	(430.28)
	<b>Net cash flow from operating activities (A)</b>	<b>2,367.23</b>	<b>1,581.85</b>
<b>B</b>	<b>Cash flows from investing activities</b>		
	Acquisition of property, plant and equipment (including capital advances, net of capital creditors)	(4,429.66)	(3,049.09)
	Bank deposits (having original maturity of more than three months)	1,237.19	206.65
	Rent received	10.81	7.51
	Interest received	52.50	81.96
	<b>Net cash used in investing activities (B)</b>	<b>(3,129.16)</b>	<b>(2,752.97)</b>
<b>C</b>	<b>Cash flows from financing activities</b>		
	Proceeds from non-current borrowings	1,565.38	1,454.67
	Repayment of non-current borrowings	(473.07)	(54.82)
	Payment of lease liabilities	(129.42)	(83.23)
	Interest and finance charges paid	(428.97)	(23.94)
	<b>Net cash from financing activities (C)</b>	<b>533.92</b>	<b>1,292.68</b>
	<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>(228.01)</b>	<b>121.56</b>
	Cash and cash equivalents at the beginning of the period	484.57	183.71
	<b>Cash and cash equivalents at the end of the period</b>	<b>256.56</b>	<b>305.27</b>
		<b>As at</b>	<b>As at</b>
		<b>September 30, 2024</b>	<b>September 30, 2023</b>
	<b>Components of cash and cash equivalents:</b>		
	Cash on hand	25.05	16.66
	Balances with banks		
	- on current accounts	231.51	288.41
		<b>256.56</b>	<b>305.27</b>



Notes:

- 1 These above unaudited financial results of KMC Speciality Hospitals (India) Limited ("the Company") for the quarter and six months ended September 30, 2024 are prepared in accordance with Indian Accounting Standard ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 2 The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on November 12, 2024 and November 13, 2024, respectively. The results for the quarter and six months ended September 30, 2024 has been reviewed by our statutory auditors. The statutory auditors have issued an unmodified review report for the quarter and six months ended September 30, 2024
- 3 The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 - "Operating Segments".

for and on behalf of the board of directors of  
KMC Speciality Hospitals (India) Limited  
CIN: L85110TN1982PLC009781

  
Dr. S. Manivannan  
Managing Director  
DIN: 00910804

Place: Chennai  
Date: November 13, 2024

